Document resource
Globally, the burden of type 2 diabetes mellitus (T2DM) continues to rise, with implications on cardiovascular risk, metabolic liver disease and cancer incidence.1 Despite advances in pharmacological management, over 50% of patients do not achieve optimal glycaemic control (HbA1c<7%), and therefore alternate approaches remain necessary.